Molecular Partners AG ADR (MOLN)
NASDAQ: MOLNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MOLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $96.80M
- EPS (TTM)
- -$1.68
- Dividend yield
- None
- 52-week range
- 2.52 – 5.36
- Day range
- 2.53 – 2.53
- Volume / Avg
- 928 / 1.63K
- Beta
- —
- Shares outstanding
- 38.34M
52-week range
MOLN stock today
Shares of Molecular Partners (MOLN) finished lower on Nov 20 at $2.53, a drop of 5.25% or $0.14 per share, versus the S&P 500's 3.70% decline. At this level, MOLN sits near the bottom of its 52-week range of $2.52 to $5.36: 52.9% below the high, set on Feb 27, 2026 and 0.2% above the low. MOLN is down 42.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 37.5%.
Molecular Partners has posted a net loss over the last twelve months (EPS of -$1.68), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Molecular Partners
Company profileMolecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Patrick Amstutz Ph.D.
- Headquarters
- Schlieren
- Employees
- 134
- IPO year
- 2021
- Website
- molecularpartners.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$9.99+295.64%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.41 vs $-0.46
- Surprise
- +10.87%
MOLN news
All MOLN news- Molecular Partners to Present at Inaugural UBS Global Biopharma ConferenceGlobeNewswire
- Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026GlobeNewswire
- Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026GlobeNewswire
- Molecular Partners AG Announces Strategic Shift to Radiopharmaceuticals and Intends to Reduce Workforce by No More Than 55 PositionsNasdaqMOLN, SUN
- Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted RadiotherapyGlobeNewswire
Molecular Partners peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs MOLN |
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs MOLN |
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs MOLN |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs MOLN |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs MOLN |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs MOLN |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs MOLN |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs MOLN |
Indexes, lists and sector
Molecular Partners stock FAQ
What is Molecular Partners's stock price today?
MOLN last traded at $2.53 as of Nov 20, 4:00 PM EST, down 5.25% on the day. Prices are delayed at least 15 minutes.
Who is Molecular Partners's CEO?
Dr. Patrick Amstutz Ph.D. is the chief executive officer of Molecular Partners AG ADR, which has about 134 employees.
What is the MOLN 52-week high?
The 52-week high for MOLN is $5.36 and the 52-week low is $2.52. The stock is currently 52.9% below its high.